Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sub-protocol D: trametinib + dexamethasone + cyclophosphamide + cytarabine in pediatric relapsed/refractory hematologic malignancies
NL-OMON60263Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), t-cell acute lymphoblastic leukemia (T-ALL) and 1 more, sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Maximum tolerated dose and Best overall response rate. Started Nov 2023; status: recruiting.
02
Drugs
trametinib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)t-cell acute lymphoblastic leukemia (T-ALL)T-lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NL-OMON60263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60263.